1
Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months
Condition(s): Hepatitis A Vaccine; Hepatitis A Last Updated: April 11, 2013Completed
53 Clinical Trials for: Havrix, Page 1 of 3
Hide Studies Not Seeking New Volunteers
2
Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines
Condition(s): Hepatitis A Last Updated: March 13, 2013Completed
3
Long-term Persistence Study in Healthy Adults Previously Vaccinated With TwinrixTM Adult
Condition(s): Hepatitis; Hepatitis A and Hepatitis B Last Updated: March 20, 2013Completed
4
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
Condition(s): Hepatitis A Vaccine; Hepatitis A Last Updated: April 11, 2013Completed
5
Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™
Condition(s): Influenza Infection Last Updated: January 31, 2013Completed
6
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
Condition(s): Hepatitis B; Typhoid; Hepatitis A Last Updated: November 17, 2011Completed
7
Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine
Condition(s): Hepatitis A Last Updated: December 18, 2012Active, not recruiting
8
Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.
Condition(s): Diphtheria; Pertussis; Hepatitis A; Tetanus Last Updated: September 29, 2011Terminated
9
Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
Condition(s): Japanese Encephalitis Last Updated: October 19, 2012Completed
10
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule
Condition(s): Hepatitis A Last Updated: March 21, 2013Active, not recruiting
11
A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children
Condition(s): Seasonal Influenza Last Updated: April 17, 2013Completed
12
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule
Condition(s): Hepatitis A Last Updated: March 7, 2013Active, not recruiting
13
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
Condition(s): Cervical Intraepithelial Neoplasia; Papillomavirus Infection Last Updated: September 13, 2012Completed
14
Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines
Condition(s): Hepatitis A Last Updated: December 18, 2012Active, not recruiting
15
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
Condition(s): Measles-Mumps-Rubella-Varicella Vaccine; Diseases Caused by Measles, Mumps, Rubella and Varicella Viruses. Last Updated: January 31, 2013Completed
16
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age
Condition(s): Measles, Mumps and Rubella Diseases Last Updated: May 9, 2013Recruiting
17
Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
Condition(s): Hepatitis A Last Updated: August 29, 2012Completed
18
A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children
Condition(s): Hepatitis A Last Updated: September 15, 2011Completed
19
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
Condition(s): Hepatitis A Last Updated: May 16, 2013Completed
20
Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination
Condition(s): Viral Hepatitis Vaccines; Hepatitis B; Hepatitis A Last Updated: June 14, 2012Completed
